STUDY OBJECTIVE: To evaluate the association of the development of acute kidney injury (AKI) when piperacillin-tazobactam is used in combination with vancomycin compared with vancomycin with or without a β-lactam. DESIGN: Meta-analysis of 15 observational cohort studies. PATIENTS: A total of 3258 adult inpatients who received vancomycin + piperacillin-tazobactam versus vancomycin alone (10 studies); vancomycin + piperacillin-tazobactam versus vancomycin + β-lactam (four studies); or vancomycin + piperacillin-tazobactam versus vancomycin alone or vancomycin + other antibiotics (one study). MEASUREMENTS AND MAIN RESULTS: The PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature, and Cochrane databases, as well as meeting proceedings, were searched (1966-June 1, 2016). Quality of studies was assessed by using the Newcastle-Ottawa Quality Assessment Scale (NOQAS). The primary outcome of this meta-analysis was to evaluate the association of development of AKI with the combined use of piperacillin-tazobactam and vancomycin. A subgroup analysis was also performed that examined the outcome by comparison groups (vancomycin alone or vancomycin + β-lactam). Sensitivity analysis was performed to explore if the results differed based on removal of abstracts and removal of low-quality studies (NOQAS scores of 6 or lower). All analyses were performed using the random effects model. NOQAS scores for the 15 studies ranged from 3-7 points (of a total of 9). Overall, there was an association with the development of AKI with vancomycin + piperacillin-tazobactam compared with vancomycin ± β-lactam (odds ratio [OR] 3.649, 95% confidence interval [CI] 2.157-6.174; I2 = 83.5%, p<0.001). The association remained significant when abstracts were removed (OR 3.498, 95% CI 1.747-7.003, I2 = 82.3%, p<0.001) and when low-quality studies were removed (OR 4.596, 95% CI 2.929-7.212, I2 = 0%, p<0.001). The association for the development of AKI with vancomycin + piperacillin-tazobactam compared with vancomycin alone was significant (OR 3.980, 95% CI 2.749-5.763, I2 = 31.4%, p<0.001), although the association did not remain significant for the vancomycin + β-lactam subgroup (OR 3.029, 95% CI 0.942-9.738, I2 = 82.3%, p=0.063). CONCLUSION: Vancomycin + piperacillin-tazobactam was associated with an increased risk of AKI compared with vancomycin ± β-lactam. Practitioners need to be vigilant about this association when prescribing this combination of antibiotics.
STUDY OBJECTIVE: To evaluate the association of the development of acute kidney injury (AKI) when piperacillin-tazobactam is used in combination with vancomycin compared with vancomycin with or without a β-lactam. DESIGN: Meta-analysis of 15 observational cohort studies. PATIENTS: A total of 3258 adult inpatients who received vancomycin + piperacillin-tazobactam versus vancomycin alone (10 studies); vancomycin + piperacillin-tazobactam versus vancomycin + β-lactam (four studies); or vancomycin + piperacillin-tazobactam versus vancomycin alone or vancomycin + other antibiotics (one study). MEASUREMENTS AND MAIN RESULTS: The PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature, and Cochrane databases, as well as meeting proceedings, were searched (1966-June 1, 2016). Quality of studies was assessed by using the Newcastle-Ottawa Quality Assessment Scale (NOQAS). The primary outcome of this meta-analysis was to evaluate the association of development of AKI with the combined use of piperacillin-tazobactam and vancomycin. A subgroup analysis was also performed that examined the outcome by comparison groups (vancomycin alone or vancomycin + β-lactam). Sensitivity analysis was performed to explore if the results differed based on removal of abstracts and removal of low-quality studies (NOQAS scores of 6 or lower). All analyses were performed using the random effects model. NOQAS scores for the 15 studies ranged from 3-7 points (of a total of 9). Overall, there was an association with the development of AKI with vancomycin + piperacillin-tazobactam compared with vancomycin ± β-lactam (odds ratio [OR] 3.649, 95% confidence interval [CI] 2.157-6.174; I2 = 83.5%, p<0.001). The association remained significant when abstracts were removed (OR 3.498, 95% CI 1.747-7.003, I2 = 82.3%, p<0.001) and when low-quality studies were removed (OR 4.596, 95% CI 2.929-7.212, I2 = 0%, p<0.001). The association for the development of AKI with vancomycin + piperacillin-tazobactam compared with vancomycin alone was significant (OR 3.980, 95% CI 2.749-5.763, I2 = 31.4%, p<0.001), although the association did not remain significant for the vancomycin + β-lactam subgroup (OR 3.029, 95% CI 0.942-9.738, I2 = 82.3%, p=0.063). CONCLUSION:Vancomycin + piperacillin-tazobactam was associated with an increased risk of AKI compared with vancomycin ± β-lactam. Practitioners need to be vigilant about this association when prescribing this combination of antibiotics.
Authors: Evan J Zasowski; Kyle P Murray; Trang D Trinh; Natalie A Finch; Jason M Pogue; Ryan P Mynatt; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191
Authors: Natalie A Finch; Evan J Zasowski; Kyle P Murray; Ryan P Mynatt; Jing J Zhao; Raymond Yost; Jason M Pogue; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.191
Authors: Adam M Blevins; Jennifer N Lashinsky; Craig McCammon; Marin Kollef; Scott Micek; Paul Juang Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191
Authors: Emily L Joyce; Sandra L Kane-Gill; Priyanka Priyanka; Dana Y Fuhrman; John A Kellum Journal: J Am Soc Nephrol Date: 2019-09-09 Impact factor: 10.121
Authors: Diana J Schreier; Kianoush B Kashani; Ankit Sakhuja; Kristin C Mara; Mohammad S Tootooni; Heather A Personett; Sarah Nelson; Andrew D Rule; James M Steckelberg; Aaron J Tande; Erin F Barreto Journal: Clin Infect Dis Date: 2019-04-24 Impact factor: 9.079